Get the Stockscreener App
1.3271
2.39%
0.0371
Editas Medicine Inc stock is traded at $1.3271, with a volume of 327.03K.
It is up +2.39% in the last 24 hours and down -1.43% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$1.29
Open:
$1.3
24h Volume:
327.03K
Relative Volume:
0.13
Market Cap:
$106.53M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-0.6474
EPS:
-2.05
Net Cash Flow:
$-136.90M
1W Performance:
-1.43%
1M Performance:
-1.43%
6M Performance:
-72.08%
1Y Performance:
-81.34%
1-Day Range:
$1.29
$1.35
1-Week Range:
$1.22
$1.43
52-Week Range:
$1.12
$11.58
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.325 | 106.53M | 78.12M | -153.22M | -136.90M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.17 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.32 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.69 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.66 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.16 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 7.6% in January - MarketBeat
Editas Medicine, Inc. to Host Earnings Call - ACCESS Newswire
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
Leerink Partnrs Comments on Editas Medicine FY2025 Earnings - MarketBeat
FY2024 EPS Estimate for Editas Medicine Decreased by Analyst - MarketBeat
Brokers Offer Predictions for Editas Medicine FY2025 Earnings - MarketBeat
Beta Thalassemia Market on Track for Major Expansion by 2034, According to DelveInsight | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers - Barchart
Beta Thalassemia Market on Track for Major Expansion by 2034, - openPR
Analysts Issue Forecasts for Editas Medicine FY2025 Earnings - MarketBeat
Hennion & Walsh Asset Management Inc. Has $340,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Position Lifted by Barclays PLC - Defense World
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
International Assets Investment Management LLC Trims Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine stock hits 52-week low at $1.16 amid steep decline - Investing.com Australia
Editas Medicine Outlines 2025 Strategic Priorities and Milestones - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
Editas Medicine stock hits 52-week low at $1.16 amid steep decline By Investing.com - Investing.com South Africa
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players - Yahoo Finance UK
Editas Medicine advances gene editing treatments - Investing.com
Editas Medicine (EDIT) Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - StreetInsider.com
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - The Manila Times
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key - The Bakersfield Californian
Editas Medicine Highlights New In Vivo Preclinical Proof of - GlobeNewswire
Editas Medicine Achieves Major Gene Editing Breakthrough in Primate Study, Sets 2027 Roadmap - StockTitan
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Editas Medicine To Present At The 43rd Annual J.P. Morgan Healthcare Conference - Barchart
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Editas Medicine CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Lowers Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Up 5.4% in December - Defense World
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by State Street Corp - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
Editas Medicine announces CMO departure and transition plan - Investing.com
JP Morgan Downgrades Editas Medicine (EDIT) - MSN
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce - MSN
EDIT Stock Falls On Decision To End Reni-Cel Studies, Cut Workforce - Barchart
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):